The test, the ReEBOV Antigen Rapid Test Kit, is a collaboration between the Tulane University-led Viral Hemorrhagic Fever Consortium and Corgenix.
The findings of two studies regarding the ReEBOV test were presented at the AACC gathering by Corgenix Program Director of Infectious Diseases and Emerging Technologies Matt Boisen. Boisen, who also was development director of the consortium, presented findings from studies by the company and the World Health Organization (WHO).
The ReEBOV test showed efficacy in the WHO study that was based in Sierra Leone and showed consistency of 91.8 percent of the time when compared with lab tests for infected samples and 84.6 percent consistency for non-affected samples.
According to the announcement, The Lancet also published a study that confirmed accuracy of the ReEBOV test. These tests also indicate that the device can be used as a complement to polymerase chain reaction (PCR) tests.
"All three studies — our internal emergency use authorization study, the WHO study and The Lancet paper — show that the rapid test can provide a plus 90 percent accuracy when paired with the PCR test," Boisen said. "This really establishes that the rapid test can be used as a triage method to quickly provide patient results that can later be confirmed by PCR. This represents a breakthrough in the detection of Ebola for this and future Ebola virus outbreaks."
The AACC annual meeting provides the chance to learn about the latest technology and studies in the medical field and related areas.